HYPDHYPERION DEFI, INC.
Is Hyperion Defi struggling financially?
Yes, by its own account. Hyperion Defi told the SEC on 5 May 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $49.4M
- Source filing
- DEF 14A 5 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
3months
If the burn speeds up
Empty by Sep 2026
-
6months
If it eases off
Empty by Dec 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$9.6M
÷
Cash burned over the last 12 months
$26.1M
What Hyperion Defi told the SEC
…audit scope or accounting principles, except that the report for the fiscal year ended December 31, 2024 included an explanatory paragraph relating to substantial doubt about the Company’s ability to continue as a going concern. During the fiscal year ended December 31, 2024 and the subsequent interim period through May 2, 2026, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation…
HYPERION DEFI, INC., Form DEF 14A, filed 5 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 334.0% share-count increase The company issued stock. Each share now owns 77.0% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 39% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- PASG Passage BIO $14.3M
- HOWL Werewolf Therapeutics $42.5M
- SCNX Scienture Holdings $18.5M
- INBS Intelligent Bio Solutions $7.6M
- ONCO Onconetix $2.6M
- INDP Indaptus Therapeutics $171.9M